Key result
Co-treatment with hesperidin protected cardiac tissues against doxorubicin-induced cardiotoxicity by ameliorating histological abnormalities and normalizing biochemical values in Wistar rats.
Why the study?
Doxorubicin use is restricted by cardiotoxicity linked to oxidative stress, and enhancing antioxidant capacity with agents such as hesperidin represents a promising cardioprotective approach.
Does hesperidin prevent doxorubicin-induced cardiotoxicity in Wistar rats?
Population
Wistar rats
Comparison
DOX plus HES vs DOX alone
Design
Animal experimental study
Follow-up
Five consecutive weeks
Authors
Loading...
Hypothesis-generating for hesperidin cardioprotection; leaves open translation to human doxorubicin regimens.
Does hesperidin prevent doxorubicin-induced cardiotoxicity in Wistar rats?
Hesperidin demonstrates significant cardioprotective effects against doxorubicin-induced cardiotoxicity in a rat model through anti-inflammatory, antioxidant, and antiapoptotic mechanisms.
Alharbi et al. (2023) studied Doxorubicin-induced cardiotoxicity. Hesperidin vs. Doxorubicin alone was evaluated on Cardiotoxicity (histological, immunohistochemical, and biochemical assessments). Co-treatment with hesperidin protected cardiac tissues against doxorubicin-induced cardiotoxicity by ameliorating histological abnormalities and normalizing biochemical values in Wistar rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: